89978-52-9

Basic information

• Product Name: ETHYL 2-BROMOISONICOTINATE
• Synonyms: RARECHEM AL BI 1524;ETHYL 2-BROMOISONICOTINATE;2-Bromopyridine-4-carboxylic acid ethyl ester;4-Pyridinecarboxylic acid, 2-broMo-, ethyl ester;ETHYL 2-BROMOISONICOTITE
• CAS NO: 89978-52-9
• Molecular Formula: C₈H₈BrNO₂
• Molecular Weight: 230.06
• Product Categories: Pyridines
• Mol File: 89978-52-9.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 282.9 °C at 760 mmHg
• Flash Point: 124.9 °C
• Appearance: /
• Density: 1.501 g/cm³
• Vapor Pressure: 0.00327mmHg at 25°C
• Refractive Index: 1.544
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.24±0.10(Predicted)
• CAS DataBase Reference: ETHYL 2-BROMOISONICOTINATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-BROMOISONICOTINATE(89978-52-9)
• EPA Substance Registry System: ETHYL 2-BROMOISONICOTINATE(89978-52-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• HazardClass: IRRITANT
• Hazardous Substances Data: 89978-52-9(Hazardous Substances Data)

Usage

General Description

Ethyl 2-bromoisonicotinate is a chemical compound with the molecular formula C8H8BrNO2. It is a yellow solid that is used in the synthesis of pharmaceuticals and as an intermediate in organic synthesis. ETHYL 2-BROMOISONICOTINATE is commonly used in the preparation of various biologically active compounds, including antiviral and antitumor agents, due to its ability to inhibit the growth of cancer cells. It is also used as a building block in the synthesis of other heterocyclic compounds and has potential applications in the development of new drugs. Ethyl 2-bromoisonicotinate is considered to be a valuable chemical in medicinal and pharmaceutical research due to its versatile reactivity and biological properties.

InChI:InChI=1/C8H8BrNO2/c1-2-12-8(11)6-3-4-10-7(9)5-6/h3-5H,2H2,1H3

Upstream product

• 66572-56-3 2-bromoisonicotinic acid 
• 64-17-5 ethanol 

Downstream Products

• 904290-69-3 ethyl 2-[2-(benzyloxy)ethoxy]isonicotinate 
• 1072198-74-3 2-(3-Cyano-4-phenylpyrrole-1-yl)isonicotinic acid ethyl ester 
• 1198793-77-9 C₁₅H₁₂F₃NO₃ 
• 1570-45-2 isonicotinic acid ethylester 

Relevant articles and documents

Discovery of a new class of JMJD6 inhibitors and structure–activity relationship study

JmjC domain-containing protein 6 (JMJD6) has been thought as a potential target for various diseases particularly cancer. However, few selective JMJD6 inhibitors have been reported. In this investigation, molecular docking and biological activity evaluation were performed to retrieve new JMJD6 inhibitors, which led to the identification of a hit compound, J2. Further structural optimization and structure–activity relationship (SAR) analysis towards J2 were carried out, which gave a new potent JMJD6 inhibitor, 7p. This compound showed an IC50 value of 0.681 μM against JMJD6, but displayed no activity against other tested JmjC domain-containing protein family members, indicating good selectivity (>100 fold). Collectively, this investigation offers a selective JMJD6 inhibitor, which could be taken as a lead compound for subsequent drug discovery targeting JMJD6.

Structure-activity relationship studies for the development of inhibitors of murine adipose triglyceride lipase (ATGL)

High serum fatty acid (FA) levels are causally linked to the development of insulin resistance, which eventually progresses to type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) generalized in the term metabolic syndrome. Adipose triglyceride lipase (ATGL) is the initial enzyme in the hydrolysis of intracellular triacylglycerol (TG) stores, liberating fatty acids that are released from adipocytes into the circulation. Hence, ATGL-specific inhibitors have the potential to lower circulating FA concentrations, and counteract the development of insulin resistance and NAFLD. In this article, we report about structure–activity relationship (SAR) studies of small molecule inhibitors of murine ATGL which led to the development of Atglistatin. Atglistatin is a specific inhibitor of murine ATGL, which has proven useful for the validation of ATGL as a potential drug target.

Syntheses of substituted pyridines, quinolines and diazines via palladium-catalyzed cross-coupling of aryl Grignard reagents

The palladium-catalyzed cross-coupling reactions between arylmagnesium halides (phenylmagnesium chloride, mesitylmagnesium bromide, 4-(methoxycarbonyl)phenylmagnesium chloride and 4-cyanophenylmagnesium chloride) and halopyridines allowed the synthesis of substituted pyridines. Owing to the remarkably mild conditions used (often below 0°C), the reaction could be extended to the use of functionalized halopyridines, haloquinolines and halodiazines.